Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.

Huszno J, Budryk M, Kołosza Z, Nowara E.

Oncology. 2013;85(5):278-82. doi: 10.1159/000354834. Epub 2013 Nov 6.

PMID:
24217135
2.

Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.

Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, Blom J, Huijskens E, Jager A, van den Ouweland A, van Geel B, Hooning MJ, Brekelmans CT, Klijn JG.

J Clin Oncol. 2009 Aug 10;27(23):3764-71. doi: 10.1200/JCO.2008.19.9067. Epub 2009 Jun 29.

PMID:
19564533
3.

Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.

Fourquet A, Stoppa-Lyonnet D, Kirova YM, Sigal-Zafrani B, Asselain B; Institut Curie Breast Cancer Study Group; Institut Curie Breast Ovary Cancer Risk Study Group.

Am J Clin Oncol. 2009 Apr;32(2):127-31. doi: 10.1097/COC.0b013e31817f9e1c.

PMID:
19307946
4.

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.

Drooger JC, Heemskerk-Gerritsen BAM, Smallenbroek N, Epskamp C, Seynaeve CM, Jager A.

Breast Cancer Res Treat. 2016 Apr;156(3):557-566. doi: 10.1007/s10549-016-3777-0. Epub 2016 Apr 9.

5.

Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.

Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD Jr, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen JH, Mellemkjaer L, Liang X, Diep AT, Borg A, Concannon P, Haile RW; WECARE Study Collaborative Group.

Eur J Cancer. 2013 Sep;49(14):2979-85. doi: 10.1016/j.ejca.2013.04.028. Epub 2013 May 21.

6.

Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy?

Raphael J, Mazouni C, Caron O, Ferchiou M, Delaloge S.

Med Oncol. 2014 Mar;31(3):850. doi: 10.1007/s12032-014-0850-6. Epub 2014 Jan 22.

PMID:
24448978
7.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

8.

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.

Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD.

Breast Cancer Res. 2004;6(1):R8-R17. Epub 2003 Oct 24.

9.

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.

Hubert A, Mali B, Hamburger T, Rottenberg Y, Uziely B, Peretz T, Kadouri L.

Fam Cancer. 2009;8(3):173-7. doi: 10.1007/s10689-008-9223-7. Epub 2008 Nov 19.

PMID:
19016350
10.

Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, Eisen A, Foulkes WD, Rosen B, Vesprini D, Sun P, Narod SA.

Breast Cancer Res Treat. 2011 May;127(1):287-96. doi: 10.1007/s10549-010-1336-7. Epub 2011 Jan 9.

PMID:
21221768
11.

[Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].

Gorodnova TV, Maksimov SIa, Guseĭnov KD, Imianitov EN.

Vopr Onkol. 2014;60(3):339-42. Russian.

PMID:
25033687
12.

Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.

Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann LC, Jenkins RB.

Cancer. 2003 Jan 1;97(1):1-11.

13.

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK.

J Clin Oncol. 2009 Dec 10;27(35):5887-92. doi: 10.1200/JCO.2008.19.9430. Epub 2009 Oct 26.

PMID:
19858402
14.

Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.

Drooger J, Akdeniz D, Pignol JP, Koppert LB, McCool D, Seynaeve CM, Hooning MJ, Jager A.

Breast Cancer Res Treat. 2015 Nov;154(1):171-80.

15.

Concurrent chemoradiotherapy in adjuvant treatment of breast cancer.

Ismaili N, Mellas N, Masbah O, Elmajjaoui S, Arifi S, Bekkouch I, Ahid S, Bazid Z, Tazi MA, Erraki A, El Mesbahi O, Benjaafar N, El Gueddari Bel K, Ismaili M, Afqir S, Errihani H.

Radiat Oncol. 2009 Apr 7;4:12. doi: 10.1186/1748-717X-4-12.

16.

Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.

de la Cruz J, Andre F, Harrell RK, Bassett RL Jr, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ.

Hum Pathol. 2012 Nov;43(11):1932-9. doi: 10.1016/j.humpath.2012.02.002. Epub 2012 May 14.

PMID:
22591913
17.

Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.

Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A; Institut Curie Breast Cancer Study Group.

Eur J Cancer. 2005 Oct;41(15):2304-11. Epub 2005 Sep 1.

PMID:
16140006
18.

Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.

Kadouri L, Sagi M, Goldberg Y, Lerer I, Hamburger T, Peretz T.

Breast Cancer Res Treat. 2013 Jul;140(1):207-11. doi: 10.1007/s10549-013-2621-z. Epub 2013 Jul 4.

PMID:
23824362
19.

Conservative management of breast cancer in BRCA1/2 mutation carriers.

Alpert TE, Haffty BG.

Clin Breast Cancer. 2004 Apr;5(1):37-42. Review.

PMID:
15140283
20.

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.

Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, Lynch CF, Concannon P, Borg A, Teraoka SN, Törngren T, Diep A, Xue S, Bertelsen L, Liang X, Reiner AS, Capanu M, Malone KE; WECARE Collaborative Study Group.

Breast Cancer Res Treat. 2010 Sep;123(2):491-8. doi: 10.1007/s10549-010-0769-3. Epub 2010 Feb 5.

Supplemental Content

Support Center